Analyst Ratings for Intellia Therapeutics
Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Raymond James Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $105
Raymond James analyst Steven Seedhouse maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $181 to $105.
Intellia Therapeutics: Q1 Earnings Insights
Intellia Therapeutics (NASDAQ:NTLA) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call
Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Credit Suisse Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $100
Credit Suisse initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Outperform rating and announces Price Target of $100.
